UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Grows Stake in Kenvue Inc. (NYSE:KVUE)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Kenvue Inc. (NYSE:KVUE) by 30.2% in the third quarter, Holdings Channel reports. The fund owned 9,992,933 shares of the company’s stock after purchasing an additional 2,316,443 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Kenvue were worth $231,137,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently bought and sold shares of KVUE. Advisors Asset Management Inc. bought a new position in shares of Kenvue in the 1st quarter worth approximately $206,000. Janus Henderson Group PLC increased its holdings in Kenvue by 53.7% during the first quarter. Janus Henderson Group PLC now owns 165,162 shares of the company’s stock valued at $3,541,000 after buying an additional 57,679 shares during the last quarter. Atria Investments Inc raised its position in Kenvue by 20.0% in the first quarter. Atria Investments Inc now owns 112,194 shares of the company’s stock worth $2,408,000 after acquiring an additional 18,663 shares during the period. Cetera Investment Advisers boosted its stake in shares of Kenvue by 183.9% during the 1st quarter. Cetera Investment Advisers now owns 449,506 shares of the company’s stock worth $9,646,000 after acquiring an additional 291,179 shares during the last quarter. Finally, Cetera Advisors LLC grew its position in shares of Kenvue by 202.0% during the 1st quarter. Cetera Advisors LLC now owns 212,097 shares of the company’s stock valued at $4,552,000 after acquiring an additional 141,858 shares during the period. Institutional investors own 97.64% of the company’s stock.

Kenvue Trading Down 0.1 %

Shares of Kenvue stock opened at $24.10 on Friday. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. The firm has a market cap of $46.20 billion, a price-to-earnings ratio of 43.81, a PEG ratio of 2.19 and a beta of 1.36. Kenvue Inc. has a twelve month low of $17.67 and a twelve month high of $24.46. The business has a 50-day moving average price of $22.94 and a 200-day moving average price of $20.99.

Kenvue (NYSE:KVUE) last released its quarterly earnings results on Thursday, November 7th. The company reported $0.28 earnings per share for the quarter, beating the consensus estimate of $0.27 by $0.01. The business had revenue of $3.90 billion during the quarter, compared to analysts’ expectations of $3.92 billion. Kenvue had a return on equity of 21.43% and a net margin of 6.88%. The firm’s revenue for the quarter was down .4% compared to the same quarter last year. During the same quarter last year, the business posted $0.31 EPS. Equities research analysts anticipate that Kenvue Inc. will post 1.07 EPS for the current fiscal year.

Kenvue Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, November 27th. Investors of record on Wednesday, November 13th were given a $0.205 dividend. This represents a $0.82 annualized dividend and a yield of 3.40%. The ex-dividend date was Wednesday, November 13th. Kenvue’s dividend payout ratio is presently 149.09%.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on KVUE. Piper Sandler raised their price objective on Kenvue from $20.00 to $21.00 and gave the stock a “neutral” rating in a research note on Monday, September 23rd. Bank of America lifted their price target on shares of Kenvue from $24.00 to $27.00 and gave the company a “buy” rating in a report on Tuesday, October 22nd. UBS Group increased their price objective on shares of Kenvue from $20.00 to $22.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 7th. Deutsche Bank Aktiengesellschaft lifted their target price on shares of Kenvue from $23.00 to $24.00 and gave the company a “buy” rating in a research note on Wednesday, August 7th. Finally, JPMorgan Chase & Co. increased their price target on Kenvue from $24.00 to $25.00 and gave the stock an “overweight” rating in a research note on Friday, October 11th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $22.64.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.